An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…
Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…
After more than 20 years of development, ADC drug is becoming the main force in cancer treatment, which, compared with traditional chemotherapy, has a wider application scope. However, minimizing ADCs’ non-target toxicityRead More…
At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…
Antibody-drug conjugate (ADC) has achieved great progress in the past decade. So far, ten ADC drugs have been approved by the FDA, of which five were approved in 2019 and 2020, andRead More…
In the last blog, we learned that the main feature of ADC candidate target antigen is that it needs to be highly expressed on the surface of tumor cells and not expressedRead More…
As we all known, antibody-drug conjugate (ADC) is a drug obtained by chemical conjuagtion of antibody, linker and cytotoxin. Compared with simple monoclonal antibodies, ADC has better targeting and more efficient killingRead More…